Veille documentaire MTPH

Auteur     Marina Bakker
Auteur     Eveline M. Bunge
Auteur     Cinzia Marano
Auteur     Marc de Ridder
Auteur     Laurence De Moerlooze
Volume     15
Numéro     7
Pages     829-851
Publication     Expert Review of Vaccines
ISSN     1744-8395
Date     Jul 2016
Extra     PMID: 26840060
Abrév. de revue     Expert Rev Vaccines
DOI     10.1586/14760584.2016.1150182
Catalogue de bibl.     PubMed
Langue     eng
Résumé     BACKGROUND: Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. OBJECTIVE: To describe the vaccine efficacy, immunogenicity, effectiveness and safety of the combined vaccine against hepatitis A and hepatitis B. METHODS: A systematic review of the literature published between 1990 and 2015. RESULTS: Anti-HAV seropositivity rates ranged from 96.2% to 100% and anti-HBs seroprotection rates from 82% to 100%. Antibodies persisted up to 15 years and geometric mean concentration (GMC) remained above the seropositivity cut-off value for both. Anti-HAV and anti-HBs immune responses were lower in less immunocompetent individuals one month after completion of the immunization schedule. The safety profiles of Twinrix(TM) and monovalent hepatitis A and B vaccines were similar. CONCLUSION: The vaccine offers satisfactory long-term immunogenicity rates, expected duration of protection and safety profile similar to the monovalent hepatitis A or B vaccines.